BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.42
+0.04 (0.54%)
Oct 3, 2024, 4:00 PM EDT - Market closed
BioCryst Pharmaceuticals Revenue
BioCryst Pharmaceuticals had revenue of $109.33M in the quarter ending June 30, 2024, with 32.54% growth. This brings the company's revenue in the last twelve months to $382.24M, up 24.65% year-over-year. In the year 2023, BioCryst Pharmaceuticals had annual revenue of $331.41M with 22.37% growth.
Revenue (ttm)
$382.24M
Revenue Growth
+24.65%
P/S Ratio
3.88
Revenue / Employee
$713,127
Employees
536
Market Cap
1.54B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
Dec 31, 2019 | 48.84M | 28.18M | 136.45% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 5.28B |
AMN Healthcare Services | 3.23B |
Teladoc Health | 2.61B |
Progyny | 1.13B |
Tilray Brands | 788.94M |
Immunocore Holdings | 280.91M |
Bicycle Therapeutics | 39.57M |
NewAmsterdam Pharma Company | 7.42M |
BCRX News
- 12 hours ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 day ago - BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome - GlobeNewsWire
- 3 days ago - U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile - GlobeNewsWire
- 16 days ago - BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks - GlobeNewsWire
- 27 days ago - BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium - GlobeNewsWire
- 4 weeks ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - BioCryst to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript - Seeking Alpha